Antitumour actions of interferons: Implications for cancer therapy

Nature Reviews Cancer

Volumn 16, Issue 3, 2016, Pages 131-144

  Parker, Belinda S ^a   Rautela, Jai ^a,b,c   Hertzog, Paul J ^d,e  

^a LA TROBE UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERFERON; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL; NEOPLASMS; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; HUMANS; INTERFERONS; NEOPLASMS;

EID: 84959531327     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.14     Document Type: Review

References (222)

1. Hertzog, P. J., & Williams, B. R. Fine tuning type I interferon responses. Cytokine Growth Factor Rev. 24, 217-225 (2013
2. Donnelly, R. P., & Kotenko, S. V. Interferon-γ: a new addition to an old family. J. Interferon Cytokine Res. 30, 555-564 (2010
3. Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. Interferon-γ: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75, 163-189 (2004
4. Kotenko, S. V., et al. IFN-γs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4, 69-77 (2003
5. Fehniger, T. A., et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL 18 or IL 15 in combination with IL 12: implications for the innate immune response. J. Immunol. 162, 4511-4520 (1999
6. Seder, R. A., Gazzinelli, R., Sher, A., & Paul, W. E. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc. Natl Acad. Sci. USA 90, 10188-10192 (1993
7. Gough, D. J., Messina, N. L., Clarke, C. J., Johnstone, R. W., & Levy, D. E. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36, 166-174 (2012
8. Hwang, S. Y., et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons α and β and alters macrophage responses. Proc. Natl Acad. Sci. USA 92, 11284-11288 (1995
9. LaFleur, D. W., et al. Interferon-?, a novel type I interferon expressed in human keratinocytes. J. Biol. Chem. 276, 39765-39771 (2001
10. Oritani, K., & Kanakura, Y. IFN-/limitin: a member of type I IFN with mild lympho-myelosuppression. J. Cell. Mol. Med. 9, 244-254 (2005
11. Fung, K. Y., et al. Interferon-protects the female reproductive tract from viral and bacterial infection. Science 339, 1088-1092 (2013
12. Lutfalla, G., et al. Mutant U5A cells are complemented by an interferon-αβ receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J. 14, 5100-5108 (1995
13. Owczarek, C. M., et al. Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2. J. Biol. Chem. 272, 23865-23870 (1997
14. Gazziola, C., et al. The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-Apoptotic effect of IFNα on pleomorphic sarcoma cells. Int. J. Oncol. 26, 129-140 (2005
15. Novick, D., Cohen, B., & Rubinstein, M. Soluble interferon-α receptor molecules are present in body fluids. FEBS Lett. 314, 445-448 (1992
16. Ambrus, J. L. Sr, et al. Free interferon-α/β receptors in the circulation of patients with adenocarcinoma. Cancer 98, 2730-2733 (2003
17. Iseda, T., Yokoyama, M., Kanayana, H., Oomoto, Y., & Kagawa, S [An investigation of serum soluble interferon receptor levels in patients with renal cell carcinoma]. Nihon Hinyokika Gakkai Zasshi 91, 514-519 (2000
18. Samarajiwa, S. A., et al. Soluble IFN receptor potentiates in vivo type I IFN signaling and exacerbates TLR4 mediated septic shock. J. Immunol. 192, 4425-4435 (2014
19. Hardy, M. P., et al. The soluble murine type I interferon receptor Ifnar 2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 97, 473-482 (2001
20. de Weerd, N. A., et al. Structural basis of a unique interferon-βsignaling axis mediated via the receptor IFNAR1. Nat. Immunol. 14, 901-907 (2013
21. Silvennoinen, O., Ihle, J. N., Schlessinger, J., & Levy, D. E. Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature 366, 583-585 (1993
22. Platanias, L. C. Mechanisms of type I-And type II interferon-mediated signalling. Nat. Rev. Immunol. 5, 375-386 (2005
23. Cheon, H., Yang, J., & Stark, G. R. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J. Interferon Cytokine Res. 31, 33-40 (2011
24. Luszczek, W., Cheriyath, V., Mekhail, T. M., & Borden, E. C. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol. Cancer Ther. 9, 2309-2321 (2010
25. Samarajiwa, S. A., Forster, S., Auchettl, K., & Hertzog, P. J. INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res. 37, D852-D857 (2009
26. Khoo, J. J., Forster, S., & Mansell, A. Toll-like receptors as interferon-regulated genes and their role in disease. J. Interferon Cytokine Res. 31, 13-25 (2011
27. Porritt, R. A., & Hertzog, P. J. Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol. 36, 150-160 (2015
28. Balkwill, F., Watling, D., & Taylor-Papadimitriou, J. Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast. Int. J. Cancer 22, 258-265 (1978
29. Hobeika, A. C., Subramaniam, P. S., & Johnson, H. M. IFNα induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene 14, 1165-1170 (1997
30. Lu, M., et al. Interferon-α targets JAK2V617F positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp. Hematol. 38, 472-480 (2010
31. Platanias, L. C., et al. CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Exp. Hematol. 27, 1315-1321 (1999
32. Cook, S. J., Rubinfeld, B., Albert, I., & McCormick, F. RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat 1 fibroblasts. EMBO J. 12, 3475-3485 (1993
33. Kumar, S., Fajardo, J. E., Birge, R. B., & Sriram, G. Crk at the quarter century mark: perspectives in signaling and cancer. J. Cell. Biochem. 115, 819-825 (2013
34. Fathers, K. E., et al. Crk adaptor proteins act as key signaling integrators for breast tumorigenesis. Breast Cancer Res. 14, R74 (2012
35. Fulda, S., & Debatin, K. M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798-4811 (2006
36. Thyrell, L., et al. Mechanisms of Interferon-Alpha induced apoptosis in malignant cells. Oncogene 21, 1251-1262 (2002
37. Choi, E. A., et al. Stat1 dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res. 63, 5299-5307 (2003
38. Bernardo, A. R., Cosgaya, J. M., Aranda, A., & Jimenez-Lara, A. M. Synergy between RA and TLR3 promotes type I IFN-dependent apoptosis through upregulation of TRAIL pathway in breast cancer cells. Cell Death Dis. 4, e479 (2013
39. Apelbaum, A., Yarden, G., Warszawski, S., Harari, D., & Schreiber, G. Type I interferons induce apoptosis by balancing cFLIP and caspase 8 independent of death ligands. Mol. Cell. Biol. 33, 800-814 (2013
40. Chawla-Sarkar, M., et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8, 237-249 (2003
41. Weber, F., Kochs, G., & Haller, O. Inverse interference: how viruses fight the interferon system. Viral Immunol. 17, 498-515 (2004
42. Hasthorpe, S., Holland, K., Nink, V., Lawler, C., & Hertzog, P. Mechanisms of resistance off NSCLC to interferons. Int. J. Oncol. 10, 933-938 (1997
43. Wagner, T. C., et al. Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int. J. Cancer 111, 32-42 (2004
44. Levin, D., Harari, D., & Schreiber, G. Stochastic receptor expression determines cell fate upon interferon treatment. Mol. Cell. Biol. 31, 3252-3266 (2011
45. Bhattacharya, S., et al. Anti-Tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. Oncogene 32, 4214-4221 (2013
46. Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., & Darnell, J. E. Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon α and interferon ?. Proc. Natl Acad. Sci. USA 93, 7673-7678 (1996
47. Levy, D. E., & Gilliland, D. G. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 19, 2505-2510 (2000
48. Balkwill, F., Taylor-Papadimitriou, J., Fantes, K. H., & Sebesteny, A. Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in athymic (nude) mice. Eur. J. Cancer 16, 569-573 (1980
49. Borden, E. C., Hogan, T. F., & Voelkel, J. G. Comparative antiproliferative activity in vitro of natural interferons α and β for diploid and transformed human cells. Cancer Res. 42, 4948-4953 (1982
50. Fuchs, S. Y. Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. J. Interferon Cytokine Res. 33, 211-225 (2013
51. Cheon, H., Borden, E. C., & Stark, G. R. Interferons and their stimulated genes in the tumor microenvironment. Semin. Oncol. 41, 156-173 (2014
52. Burnet, M. Cancer: a biological approach. I. The processes of control. Br. Med. J. 1, 779-786 (1957
53. Burnet, F. M. Immunological surveillance in neoplasia. Transplant. Rev. 7, 3-25 (1971
54. Dunn, G. P., Old, L. J., & Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360 (2004
55. Gresser, I., Maury, C., & Brouty-Boye, D. Mechanism of the antitumour effect of interferon in mice. Nature 239, 167-168 (1972
56. Dunn, G. P., et al. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6, 722-729 (2005
57. Liu, Y. J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23, 275-306 (2005
58. Liu, C., et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J. Clin. Invest. 118, 1165-1175 (2008
59. Treilleux, I., et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 10, 7466-7474 (2004
60. Sisirak, V., et al. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T cell expansion that may contribute to breast cancer progression. Cancer Res. 72, 5188-5197 (2012
61. Bidwell, B. N., et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18, 1224-1231 (2012
62. Greiner, J. W., et al. Enhanced expression of surface tumor-Associated antigens on human breast and colon tumor cells after recombinant human leukocyte α-interferon treatment. Cancer Res. 44, 3208-3214 (1984
63. Boyer, C. M., et al. Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines. Cancer Res. 49, 2928-2934 (1989
64. Schiavoni, G., Mattei, F., & Gabriele, L. Type I interferons as stimulators of DC mediated cross-priming: impact on anti-Tumor response. Front. Immunol. 4, 483 (2013
65. Joffre, O. P., Segura, E., Savina, A., & Amigorena, S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12, 557-569 (2012
66. Curtsinger, J. M., & Mescher, M. F. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22, 333-340 (2010
67. Fuertes, M. B., et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J. Exp. Med. 208, 2005-2016 (2011
68. Pace, L., et al. APC activation by IFN-Alpha decreases regulatory T cell and enhances Th cell functions. J. Immunol. 184, 5969-5979 (2010
69. Srivastava, S., Koch, M. A., Pepper, M., & Campbell, D. J. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J. Exp. Med. 211, 961-974 (2014
70. Zoglmeier, C., et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin. Cancer Res. 17, 1765-1775 (2011
71. Wang, Z. K., et al. Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunol. Immunother. 61, 911-916 (2012
72. Watanabe, M. A., Oda, J. M., Amarante, M. K., & Cesar Voltarelli, J. Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev. 29, 569-579 (2010
73. Duluc, D., et al. Interferon-γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-Associated macrophages. Int. J. Cancer 125, 367-373 (2009
74. Propper, D. J., et al. Low-dose IFN-γ induces tumor MHC expression in metastatic malignant melanoma. Clin. Cancer Res. 9, 84-92 (2003
75. Boehm, U., Klamp, T., Groot, M., & Howard, J. C. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15, 749-795 (1997
76. Schreiner, B., et al. Interferon-β enhances monocyte and dendritic cell expression of B7 H1 (PD L1), a strong inhibitor of autologous T cell activation: relevance for the immune modulatory effect in multiple sclerosis. J. Neuroimmunol. 155, 172-182 (2004
77. Eppihimer, M. J., et al. Expression and regulation of the PD L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 9, 133-145 (2002
78. Mattei, F., Schiavoni, G., Belardelli, F., & Tough, D. F. IL 15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J. Immunol. 167, 1179-1187 (2001
79. Anthony, S. M., Howard, M. E., Hailemichael, Y., Overwijk, W. W., & Schluns, K. S. Soluble interleukin 15 complexes are generated in vivo by type I interferon dependent and independent pathways. PLoS ONE 10, e0120274 (2015
80. Burkett, P. R., et al. Coordinate expression and trans presentation of interleukin (IL)-15Rα and IL 15 supports natural killer cell and memory CD8+ T cell homeostasis. J. Exp. Med. 200, 825-834 (2004
81. Sathe, P., et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat. Commun. 5, 4539 (2014
82. Waldmann, T. A. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol. Res. 3, 219-227 (2015
83. Nguyen, K. B., et al. Coordinated and distinct roles for IFN-αβ, IL 12, and IL 15 regulation of NK cell responses to viral infection. J. Immunol. 169, 4279-4287 (2002
84. Herberman, R. B., Ortaldo, J. R., Rubinstein, M., & Pestka, S. Augmentation of natural and antibody-dependent cell-mediated cytotoxicity by pure human leukocyte interferon. J. Clin. Immunol. 1, 149-153 (1981
85. Spits, H., et al. Innate lymphoid cells-A proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145-149 (2013
86. Lanier, L. L. NK cell recognition. Annu. Rev. Immunol. 23, 225-274 (2005
87. Fregni, G., Perier, A., Avril, M. F., & Caignard, A. NK cells sense tumors, course of disease and treatments: consequences for NK based therapies. Oncoimmunology 1, 38-47 (2012
88. Swann, J. B., et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178, 7540-7549 (2007
89. Gresser, I., Belardelli, F., Maury, C., Maunoury, M. T., & Tovey, M. G. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J. Exp. Med. 158, 2095-2107 (1983
90. Deonarain, R., et al. Critical roles for IFN-β in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc. Natl Acad. Sci. USA 100, 13453-13458 (2003
91. Koromilas, A. E., & Sexl, V. The tumor suppressor function of STAT1 in breast cancer. JAKSTAT 2, e23353 (2013
92. Kaplan, D. H., et al. Demonstration of an interferon ?-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95, 7556-7561 (1998
93. Bi, X., et al. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res. 13, R111 (2011
94. Wong, L. H., et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48 ISGF3?. J. Biol. Chem. 272, 28779-28785 (1997
95. Landolfo, S., et al. Chronic myeloid leukemia cells resistant to interferon-α lack STAT1 expression. Hematol. J. 1, 7-14 (2000
96. Slattery, M. L., Lundgreen, A., Bondurant, K. L., & Wolff, R. K. Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis 32, 1660-1667 (2011
97. Stiff, A., & Carson, W. III. Investigations of interferon-γ for the treatment of cancer. J. Innate Immun. 7, 243-250 (2015
98. De Lustig, E. S., Cortade de De La Pena, N., & Canonico, A. Interferon in breast cancer. Tumori 63, 155-162 (1977
99. Widschwendter, A., et al. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin. Cancer Res. 8, 3065-3074 (2002
100. Sun, Y., Yang, S., Sun, N., & Chen, J. Differential expression of STAT1 and p21 proteins predicts pancreatic cancer progression and prognosis. Pancreas 43, 619-623 (2014
101. Ahtiainen, L., et al. Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus. PLoS ONE 5, e13859 (2010
102. Platanias, L. C. Interferons and their antitumor properties. J. Interferon Cytokine Res. 33, 143-144 (2013
103. Stein, B. L., & Tiu, R. V. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J. Interferon Cytokine Res. 33, 145-153 (2013
104. Hervas-Stubbs, S., et al. Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res. 17, 2619-2627 (2011
105. Talpaz, M., Hehlmann, R., Quintas-Cardama, A., Mercer, J., & Cortes, J. Re emergence of interferon-α in the treatment of chronic myeloid leukemia. Leukemia 27, 803-812 (2013
106. Ascierto, P. A., et al. Interferon α for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. J. Chemother. 26, 193-201 (2014
107. Kirkwood, J. M., et al. High-dose interferon alfa 2b significantly prolongs relapse-free and overall survival compared with the GM2 KLH/QS 21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19, 2370-2380 (2001
108. Mocellin, S., Pasquali, S., Rossi, C. R., & Nitti, D. Interferon α adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-Analysis. J. Natl Cancer Inst. 102, 493-501 (2010
109. Pasquali, S., & Mocellin, S. The anticancer face of interferon α (IFN-α): from biology to clinical results, with a focus on melanoma. Curr. Med. Chem. 17, 3327-3336 (2010
110. Akman, T., et al. Long-Term outcomes and prognostic factors of high-risk malignant melanoma patients after surgery and adjuvant high-dose interferon treatment: a single-center experience. Chemotherapy 60, 228-238 (2014
111. Kilbridge, K. L., et al. Patient preferences for adjuvant interferon α 2b treatment. J. Clin. Oncol. 19, 812-823 (2001
112. de La Salmoniere, P., Grob, J. J., Dreno, B., Delaunay, M., & Chastang, C. White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma. Clin. Cancer Res. 6, 4713-4718 (2000
113. Colombo, N., et al. Anti-Tumor and immunomodulatory activity of intraperitoneal IFN-γ in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int. J. Cancer 51, 42-46 (1992
114. Veronese, F. M., & Mero, A. The impact of PEGylation on biological therapies. BioDrugs 22, 315-329 (2008
115. Tseng, T. C., Kao, J. H., & Chen, D. S. Peginterferon α in the treatment of chronic hepatitis B. Expert Opin. Biol. Ther. 14, 995-1006 (2014
116. Druyts, E., et al. Efficacy and safety of pegylated interferon alfa 2a or alfa 2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-Analysis. Clin. Infect. Dis. 56, 961-967 (2013
117. Eggermont, A. M., et al. Adjuvant therapy with pegylated interferon alfa 2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372, 117-126 (2008
118. Eggermont, A. M., et al. Long-Term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa 2b versus observation in resected stage III melanoma. J. Clin. Oncol. 30, 3810-3818 (2012
119. Daud, A., et al. Management of pegylated interferon α toxicity in adjuvant therapy of melanoma. Expert Opin. Biol. Ther. 12, 1087-1099 (2012
120. Rozati, S., Naef, L., Levesque, M. P., French, L. E., & Dummer, R. Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy. J. Immunother. 36, 52-56 (2013
121. Tarhini, A. A., & Kirkwood, J. M. How much of a good thing? What duration for interferon alfa 2b adjuvant therapy? J. Clin. Oncol. 30, 3773-3776 (2012
122. Aranda, F., et al. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology 3, e29179 (2014
123. Qin, M., Li, Y., Yang, X., & Wu, H. Safety of Toll-like receptor 9 agonists: a systematic review and meta-Analysis. Immunopharmacol. Immunotoxicol. 36, 251-260 (2014
124. Hartman, L. L., et al. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J. Pediatr. Hematol. Oncol. 36, 451-457 (2014
125. Jeung, H. C., et al. Phase III trial of adjuvant 5 fluorouracil and adriamycin versus 5 fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (polyA: U) for locally advanced gastric cancer after curative surgery: final results of 15 year follow up. Ann. Oncol. 19, 520-526 (2008
126. Kemeny, N., et al. Randomized trial of standard therapy with or without poly I: C in patients with superficial bladder cancer. Cancer 48, 2154-2157 (1981
127. Gutterman, J. U., et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann. Intern. Med. 93, 399-406 (1980
128. Borden, E. C., et al. Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann. Intern. Med. 97, 1-6 (1982
129. Sherwin, S. A., et al. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248, 2461-2466 (1982
130. Sherwin, S. A., et al. Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial. Ann. Intern. Med. 98, 598-602 (1983
131. Muss, H. B., et al. A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer. J. Clin. Oncol. 2, 1012-1016 (1984
132. Nethersell, A., Smedley, H., Katrak, M., Wheeler, T., & Sikora, K. Recombinant interferon in advanced breast cancer. Br. J. Cancer 49, 615-620 (1984
133. Padmanabhan, N., Balkwill, F. R., Bodmer, J. G., & Rubens, R. D. Recombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trial. Br. J. Cancer 51, 55-60 (1985
134. Quesada, J. R., et al. Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am. J. Med. 77, 427-432 (1984
135. Pouillart, P., et al. Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone receptors. Eur. J. Cancer Clin. Oncol. 18, 929-935 (1982
136. Quesada, J. R., Gutterman, J. U., & Hersh, E. M. Clinical and immunological study of beta interferon by intramuscular route in patients with metastatic breast cancer. J. Interferon Res. 2, 593-599 (1982
137. Bruntsch, U., Groos, G., Tigges, F. J., Hofschneider, P. H., & Gallmeier, W. M. Lack of response in nine patients with breast cancer treated with fibroblast interferon. Cancer Chemother. Pharmacol. 13, 39-42 (1984
138. Laszlo, J., Hood, L., Cox, E., & Goodwin, B. A randomized trial of low doses of alpha interferon in patients with breast cancer. J. Biol. Response Mod. 5, 206-210 (1986
139. Naso, C., et al. Lymphoblastoid interferon in advanced breast cancer: a phase II study. J. Chemother. 5, 258-261 (1993
140. Sarna, G. P., & Figlin, R. A. Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancer. Cancer Treat. Rep. 69, 547-549 (1985
141. van den Berg, H. W., Leahey, W. J., Lynch, M., Clarke, R., & Nelson, J. Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR 75 1) and sensitizes them to the anti-proliferative effects of tamoxifen. Br. J. Cancer 55, 255-257 (1987
142. Sica, G., et al. Effect of natural beta-interferon on estrogen receptor mRNA of breast cancer cells. Anticancer Res. 12, 2061-2064 (1992
143. Sica, G., Natoli, V., Stella, C., & Del Bianco, S. Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer 60, 2419-2423 (1987
144. Seymour, L., & Bezwoda, W. R. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators. Br. J. Cancer 68, 352-356 (1993
145. Sica, G., et al. Steroid receptor enhancement by natural interferon-beta in advanced breast cancer. Eur. J. Cancer 29A, 329-333 (1993
146. Di Martino, L., Demontis, B., Saccani Iotti, G., & Murenu, G. In vivo effect induced by interferon beta on steroid receptor status, cell kinetics and DNA ploidy in operable breast cancer patients. Anticancer Res. 15, 537-541 (1995
147. Kornek, G., et al. Effect of interferon alpha 2a on hormone receptor status in patients with advanced breast cancer. Cancer Invest. 17, 189-194 (1999
148. Buzzi, E., et al. Natural interferon-beta and tamoxifen in hormone-resistant patients with advanced breast cancer. Anticancer Res. 15, 2187-2190 (1995
149. Buzzi, F., et al. Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer. Anticancer Res. 12, 869-871 (1992
150. Miglietta, L., et al. Tamoxifen and alpha interferon in advanced breast cancer. J. Chemother. 3, 383-386 (1991
151. Macheledt, J. E., et al. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res. Treat. 18, 165-170 (1991
152. Repetto, L., et al. Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. Breast Cancer Res. Treat. 39, 235-238 (1996
153. Barak, V., et al. Changes in cytokine production of breast cancer patients treated with interferons. Cytokine 10, 977-983 (1998
154. Lama, G., Angelucci, C., Recchia, F., & Sica, G. Combined effects of 13 cis-retinoic acid, tamoxifen and interferon on the growth of human breast cancer cells. Cancer Lett. 100, 181-189 (1996
155. Recchia, F., et al. Beta-interferon, retinoids and tamoxifen combination in advanced breast cancer. Clin. Ter. 149, 203-208 (1998
156. Recchia, F., et al. Beta-interferon, retinoids and tamoxifen in metastatic breast cancer: long-Term follow up of a phase II study. Oncol. Rep. 21, 1011-1016 (2009
157. Recchia, F., et al. Interferon-beta, retinoids, and tamoxifen in the treatment of metastatic breast cancer: a phase II study. J. Interferon Cytokine Res. 15, 605-610 (1995
158. Chiesa, M. D., et al. Tamoxifen versus tamoxifen plus 13 cis-retinoic acid versus tamoxifen plus interferon alpha 2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial. Acta Biomed. 78, 204-209 (2007
159. Schreiber, G., & Piehler, J. The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol. 36, 139-149 (2015
160. Welander, C. E. Overview of preclinical and clinical studies of interferon alfa 2b in combination with cytotoxic drugs. Invest. New Drugs 5 (Suppl.), S47-S59 (1987
161. Pronzato, P., et al. Cisplatin and recombinant alpha interferon in advanced breast cancer. Ann. Oncol. 1, 150-151 (1990
162. Walters, R. S., Theriault, R. L., Booser, D. J., Esparza, L., & Hortobagyi, G. N. Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5 fluorouracil in metastatic breast cancer. J. Immunother. Emphasis Tumor Immunol. 18, 185-187 (1995
163. Iaffaioli, R. V., et al. Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. Breast Cancer Res. Treat. 35, 243-248 (1995
164. Oldham, R. K., Blumenschein, G., Schwartzberg, L., Birch, R., & Arnold, J. Combination biotherapy utilizing interleukin 2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol. Biother. 4, 4-9 (1992
165. Walters, R. S., Theriault, R. L., Holmes, F. A., Esparza, L., & Hortobagyi, G. N. Phase II study of recombinant alpha-interferon and recombinant interleukin 2 metastatic breast cancer. J. Immunother. Emphasis Tumor Immunol. 16, 303-305 (1994
166. Kimmick, G., et al. Subcutaneously administered recombinant human interleukin 2 and interferon alfa 2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest. New Drugs 22, 83-89 (2004
167. Orita, K., Fuchimoto, S., Kurimoto, M., Ando, S., & Minowada, J. Early phase II study of interferon-Alpha and tumor necrosis factor-Alpha combination in patients with advanced cancer. Acta Med. Okayama 46, 103-112 (1992
168. Nicolini, A., & Carpi, A. Beta-interferon and interleukin 2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. Biomed. Pharmacother. 59, 253-263 (2005
169. Nicolini, A., Carpi, A., & Rossi, G. An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunologic parameters. J. Immunother. 28, 276-279 (2005
170. Nicolini, A., Carpi, A., & Rossi, G. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. Cancer Lett. 251, 330-338 (2007
171. Ducret, J. P., et al. A phase I clinical tolerance study of polyadenylic-polyuridylic acid in cancer patients. J. Biol. Response Mod. 4, 129-133 (1985
172. Lacour, J., et al. Adjuvant treatment with polyadenylic-polyuridylic acid (Polya. Polyu) in operable breast cancer. Lancet 2, 161-164 (1980
173. Lacour, J. Clinical trials using polyadenylic-polyuridylic acid as an adjuvant to surgery in treating different human tumors. J. Biol. Response Mod. 4, 538-543 (1985
174. Lacour, J., et al. Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial. Br. Med. J. (Clin. Res. Ed.) 288, 589-592 (1984
175. Laplanche, A., et al. Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow up analysis of a randomized trial of the Federation Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Res. Treat. 64, 189-191 (2000
176. Salaun, B., et al. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res. 71, 1607-1614 (2011
177. Rack, B., et al. Circulating tumor cells predict survival in early average-To high risk breast cancer patients. J. Natl Cancer Inst. 106, dju066 (2014
178. Giuliano, M., et al. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 16, 440 (2014
179. Braun, S., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793-802 (2005
180. Sun, W. H., et al. Interferon-Alpha resistance in a cutaneous T cell lymphoma cell line is associated with lack of STAT1 expression. Blood 91, 570-576 (1998
181. Sistigu, A., et al. Cancer cell-Autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301-1309 (2014
182. Berry, M. P., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973-977 (2010
183. Chiche, L., et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 66, 1583-1595 (2014
184. Kirkwood, J. Cancer immunotherapy: the interferon-Alpha experience. Semin. Oncol. 29, 18-26 (2002
185. Mattarollo, S. R., et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 71, 4809-4820 (2011
186. Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39, 74-88 (2013
187. Stagg, J., et al. Anti-ErbB 2 mAb therapy requires type I and II interferons and synergizes with anti PD 1 or anti CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108, 7142-7147 (2011
188. Hannesdottir, L., et al. Lapatinib and doxorubicin enhance the Stat1 dependent antitumor immune response. Eur. J. Immunol. 43, 2718-2729 (2013
189. Slaney, C. Y., Rautela, J., & Parker, B. S. The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res. 73, 5852-5857 (2013
190. Formenti, S. C., & Demaria, S. Systemic effects of local radiotherapy. Lancet Oncol. 10, 718-726 (2009
191. Demaria, S., Pilones, K. A., Vanpouille-Box, C., Golden, E. B., & Formenti, S. C. The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat. Res. 182, 170-181 (2014
192. Naidoo, J., Page, D. B., & Wolchok, J. D. Immune modulation for cancer therapy. Br. J. Cancer 111, 2214-2219 (2014
193. Hertzog, P., Forster, S., & Samarajiwa, S. Systems biology of interferon responses. J. Interferon Cytokine Res. 31, 5-11 (2011
194. Krysko, D. V., et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860-875 (2012
195. Ghiringhelli, F., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL 1β dependent adaptive immunity against tumors. Nat. Med. 15, 1170-1178 (2009
196. Obeid, M., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2007
197. Schiavoni, G., et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71, 768-778 (2011
198. Yamaguchi, R., et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum. Pathol. 43, 1688-1694 (2012
199. Litterman, A. J., Dudek, A. Z., & Largaespada, D. A. Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-Antigen-Targeting anticancer vaccination. Oncoimmunology 2, e26294 (2013
200. Nielsen, J. S., et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 18, 3281-3292 (2012
201. de Visser, K. E., Korets, L. V., & Coussens, L. M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423 (2005
202. Olkhanud, P. B., et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T regulatory cells. Cancer Res. 71, 3505-3515 (2011
203. Watanabe, N., et al. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of ?δ T cells expanded from peripheral blood cells by stimulation with zoledronate. Cytotherapy 8, 118-129 (2006
204. Bacher, N., et al. Interferon-Alpha suppresses cAMP to disarm human regulatory T cells. Cancer Res. 73, 5647-5656 (2013
205. Braun, D., Caramalho, I., & Demengeot, J. IFN-Alpha/beta enhances BCR-dependent B cell responses. Int. Immunol. 14, 411-419 (2002
206. Le Bon, A., et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by Type I IFN. J. Immunol. 176, 2074-2078 (2006
207. Swanson, C. L., et al. Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J. Exp. Med. 207, 1485-1500 (2010
208. Bui, J. D., Carayannopoulos, L. N., Lanier, L. L., Yokoyama, W. M., & Schreiber, R. D. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J. Immunol. 176, 905-913 (2006
209. Yadav, D., Ngolab, J., Lim, R. S., Krishnamurthy, S., & Bui, J. D. Cutting edge: down-regulation of MHC class I related chain A on tumor cells by IFN-gamma-induced microRNA. J. Immunol. 182, 39-43 (2009
210. Piontek, G. E., et al. YAC 1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J. Immunol. 135, 4281-4288 (1985
211. Yang, I., et al. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-Alpha and interferon-gamma treatment of human glioblastoma multiforme. J. Neurosurg. 100, 310-319 (2004
212. Biron, C. A., Sonnenfeld, G., & Welsh, R. M. Interferon induces natural killer cell blastogenesis in vivo. J. Leukoc. Biol. 35, 31-37 (1984
213. Marrack, P., Kappler, J., & Mitchell, T. Type I interferons keep activated T cells alive. J. Exp. Med. 189, 521-530 (1999
214. Brinkmann, V., Geiger, T., Alkan, S., & Heusser, C. H. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J. Exp. Med. 178, 1655-1663 (1993
215. Zhang, X., Sun, S., Hwang, I., Tough, D F., & Sprent, J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL 15. Immunity 8, 591-599 (1998
216. Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., & Salazar-Mather, T. P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220 (1999
217. Jereb, B., Us Krasovec, M., Cervek, J., & Soos, E. Intrapleural application of human leukocyte interferon (HLI) in breast cancer patients with ipsilateral pleural carcinomatosis. J. Interferon Res. 7, 357-363 (1987
218. Muss, H. B., et al. Recombinant gamma interferon in advanced breast cancer: a phase II trial. Invest. New Drugs 4, 377-381 (1986
219. Barreras, L., Vogel, C. L., Koch, G., & Marcus, S. G. Phase II trial of recombinant beta (IFN-betaser) interferon in the treatment of metastatic breast cancer. Invest. New Drugs 6, 211-215 (1988
220. Amoroso, D., et al. Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: results of a multicentric phase II trial. Breast Cancer Res. Treat. 33, 265-268 (1995
221. Fentiman, I. S., Balkwill, F. R., Cuzick, J., Hayward, J. L., & Rubens, R. D. A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrence. Eur. J. Surg. Oncol. 13, 425-428 (1987
222. Buzdar, A. U., et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J. Clin. Oncol. 10, 1540-1546 (1992